公开(公告)号：US20230113633A1

公开(公告)日：2023-04-13

申请号：US18081322

申请日：2022-12-14

Applicant: TANAKA KIKINZOKU KOGYO K.K. ,  TOKUSHIMA UNIVERSITY

Inventor： Michimasa OKUBO ,  Kenji GOTO ,  Kunihiro TANAKA ,  Kojiro SHIRAISHI ,  Kunihiro SHIMA ,  Yuya KATO ,  Kenichi HAMADA ,  Eiichi HONDA ,  Emi TAKEGAWA

IPC: C22C5/02 ,  A61L29/02 ,  A61L31/02 ,  C22F1/14

Abstract: The present invention relates to a medical Au-Pt-Pd alloy including Au, Pt,Pd, and inevitable impurities. The Au-Pt-Pd alloy has an alloy compositioninside a polygon (A1-A2-A3-A4) surrounded by straight lines connected at pointA1 (Au: 53 atom%, Pt: 4 atom%, and Pd: 43 atom%), point A2 (Au: 70 atom%,Pt: 4 atom%, and Pd: 26 atom%), point A3 (Au: 69.9 atom%, Pt: 30 atom%, and Pd: 0.1 atom%), and point A4 (Au: 49.9 atom%, Pt: 50 atom%, and Pd: 0.1 atom%) in a Au-Pt-Pd ternary state diagram. In a metal structure of the alloy, at least one of a Au-rich phase and a Pt-rich phase is distributed, and the total of the area ratio of the Au-rich phase and the area ratio of the Pt-rich phase is 1.5% or more and 25.4% or less.

公开(公告)号：US20230040395A1

公开(公告)日：2023-02-09

申请号：US17757610

申请日：2020-12-18

Applicant: DAICEL CORPORATION ,  NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY ,  TOKUSHIMA UNIVERSITY

Inventor： Takanori NAKAJIMA ,  Yoko YAMASHITA ,  Hitoshi ASHIDA ,  Rie MUKAI

IPC: A61K31/352 ,  A61P3/04 ,  A23L33/10 ,  A23L2/52

Abstract: The present disclosure addresses the problem of providing at least a composition for suppressing obesity and the problem is solved by a composition for suppressing obesity comprising a prenylflavonoid represented by general formula (1), as an active ingredient, below.

公开(公告)号：US20220227887A1

公开(公告)日：2022-07-21

申请号：US17617781

申请日：2020-06-10

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  TOKUSHIMA UNIVERSITY

Inventor： Taku OKAZAKI ,  Daisuke SUGIURA ,  II-mi OKAZAKI ,  Shiro SHIBAYAMA

IPC: C07K16/46 ,  A61P37/06 ,  A61P37/08 ,  C07K16/28

Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.

公开(公告)号：US11000572B2

公开(公告)日：2021-05-11

申请号：US16671497

申请日：2019-11-01

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Akihito Yamamoto ,  Minoru Ueda ,  Kohki Matsubara ,  Akio Suzumura ,  Koichi Furukawa ,  Yoshihiro Matsushita ,  Hirotaka Wakayama ,  Nobunori Takahashi ,  Shin Tsunekawa ,  Takako Izumoto

IPC: A61K38/19 ,  C12N5/0786 ,  A61K45/06 ,  A61K31/737 ,  A61K38/17

Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

公开(公告)号：US20200347165A1

公开(公告)日：2020-11-05

申请号：US16762221

申请日：2018-11-14

Applicant: TOKUSHIMA UNIVERSITY ,  SEKISUI CHEMICAL CO., LTD.

Inventor： Koichi UTE ,  Tomohiro HIRANO ,  Miyuki OSHIMURA ,  Yasunari KUSAKA ,  Yohei NISHIMURA ,  Misaki SENOO

IPC: C08F218/08 ,  C08F216/06

Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and capable of providing a film having high flexibility, high mechanical strength, and high adhesion, and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a triad unit chain ratio TOO of 7.5 or less, where the triad unit chain ratio TOO is obtained using the following formula (1): [ Math .  1 ] T OO = [ Vac   content ] × [ OOO   proportion ] × 2 [ VOH   content ] × [ AOO   proportion ] ( 1 ) wherein the VOH content ratio represents the amount of the unit of vinyl alcohol, the Vac content ratio represents the amount of the unit of vinyl acetate, the OOO proportion represents the proportion of a triad OOO, and the AOO proportion represents the proportion of a triad AOO.

公开(公告)号：US20200255474A1

公开(公告)日：2020-08-13

申请号：US16631141

申请日：2018-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa KATAGIRI ,  Tetsuro YOSHIMARU ,  Takashi MIYAMOTO ,  Yasuhide OKAMOTO

IPC: C07K7/08 ,  A61P35/00 ,  A61K47/65

Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

公开(公告)号：US10711081B2

公开(公告)日：2020-07-14

申请号：US16098478

申请日：2017-05-08

Applicant: TOKUSHIMA UNIVERSITY ,  SEKISUI CHEMICAL CO., LTD.

Inventor： Koichi Ute ,  Tomohiro Hirano ,  Miyuki Oshimura ,  Yasunari Kusaka

IPC: C08F216/06 ,  C08F218/08 ,  C08F8/14 ,  C08F216/38 ,  C08F8/12 ,  B01J31/12

Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a randomness value R of 0.5 or higher, the randomness value R being obtained using the following equation (1): R = 1 L A + 1 L O ( 1 ) where LO represents a mean chain length of the unit of vinyl alcohol and LA represents a mean chain length of the unit of vinyl acetate.

公开(公告)号：US10669310B2

公开(公告)日：2020-06-02

申请号：US16070896

申请日：2017-01-16

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Takashi Miyamoto ,  Rie Hayashi

IPC: A61K38/10 ,  C07K7/04 ,  A61K38/00 ,  C07K7/00 ,  A61P35/00 ,  A61K38/03

Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.

公开(公告)号：US10507230B2

公开(公告)日：2019-12-17

申请号：US15938839

申请日：2018-03-28

Applicant: TOKUSHIMA UNIVERSITY

Inventor： Akihito Yamamoto ,  Minoru Ueda ,  Kohki Matsubara ,  Akio Suzumura ,  Koichi Furukawa ,  Yoshihiro Matsushita ,  Hirotaka Wakayama ,  Nobunori Takahashi ,  Shin Tsunekawa ,  Takako Izumoto

IPC: A61K38/19 ,  C12N5/00 ,  C12N5/0786 ,  A61K45/06 ,  A61K31/737 ,  A61K38/17

Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

公开(公告)号：US09409972B2

公开(公告)日：2016-08-09

申请号：US14193362

申请日：2014-02-28

Applicant: SAISEI MIRAI CLINIC ,  TOKUSHIMA UNIVERSITY

Inventor： Yoshihiro Uto ,  Hitoshi Hori ,  Toshio Inui ,  Kentaro Kubo

IPC: A01N65/00 ,  C07K14/765 ,  A61K35/16 ,  A61K38/47

CPC classification number: C07K14/765 ,  A61K35/16 ,  A61K38/47

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract translation: 本发明的目的是提供一种药物组合物及其制备方法，其包含可用于治疗和预防诸如癌症和感染性疾病的疾病的经酶处理的人血清。 本发明涉及一种制备包含经酶处理的人血清的药物组合物的方法，包括使人血清与β-半乳糖苷酶接触的步骤，以及包含经酶处理的人血清 制备方法。